CLDN4

(redirected from claudin 4)

CLDN4

A gene on chromosome 7q11.23 that encodes claudin-4, an integral membrane protein of the claudin family, the members of which form part of the tight junction strands and may play a role in embryonic and post-natal organogenesis and function.

Molecular pathology
CLDN4 is deleted in Williams-Beuren syndrome, a multisystem neurodevelopmental disorder.
Mentioned in ?
References in periodicals archive ?
3) Immunofluorescent staining of cultured cells at 48 hours show that TGF-[beta]1-treated, PTEN-deficient-mutant cells exhibited decreased expressions of zonula occludens-1 and claudin 4 compared with green fluorescent protein and PTEN wild types.
Those genes included VEGF, BCL2, claudin 4 (CLDN4), Yes-associated protein 1 (YAP1), and c-MET, and each was found to significantly predict recurrence-free survival following radiotherapy or chemoradiotherapy.
Those markers include von Hippel-Lindau tumor suppressor (pVHL), placental S100 (S100P), mammary serine protease inhibitor (maspin), insulin-like growth factor II messenger RNA binding protein-3 (IMP3), mesothelin, prostate stem cell antigen (PSCA), annexin A8, fascin, claudin 4, claudin 18, p53, SMAD family member 4 (DPC4/SMAD4), carcinoembryonic antigen (CEA), cytokeratin (CK) 17, CK19, mucin (MUC) 1, MUC2, MUC5AC, cancer antigen 19-9 (CA19-9), and EPCAM.
2, CK7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/SMAD4, caudal type homeobox 2 [CDX2], pVHL, S100P, IMP3, maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA, EPCAM, CEA, and CA19-9) in 60 cases of pancreatic DADC on tissue microarray and routine tissue sections.
Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions.
Usefulness of claudin 4 in the cytological diagnosis of serosal effusions.
2, CK [cytokeratin] 7, CK20, CK17, CK19, MUC1, MUC2, MUC4, MUC5AC, MUC6, p53, DPC4/ SMAD4, CDX2, pVHL [von Hippel-Lindau tumor suppressor gene protein], S100P, IMP-3 [insulin-like growth factor 2 messenger RNA binding protein 3], maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA [prostate stem cell antigen], MOC31, CEA [carcinoembryonic antigen], and CA19-9 [cancer antigen 19-9]) in the diagnosis of ductal adenocarcinoma of the pancreas by using 60 cases of pancreatic DAC on routine and tissue microarray (TMA) sections.
2, CK7, CK20, CK17, CK19); (2) mucin gene products (MUC1, MUC2, MUC4, MUC5AC, MUC6); (3) tumor suppressor genes and transcription factors (p53, DPC4/SMAD4, CDX2, pVHL); and (4) tumor-associated proteins (S100P, IMP-3, maspin, mesothelin, claudin 4, claudin 18, annexin A8, fascin, PSCA, MOC31, CEA, CA19-9).
2, CK7, CK19, MUC1, MUC6, CA19-9, MOC31, PSCA, mesothelin, an nexin A8, claudin 4, and claudin 18; (4) normal pancreatic ducts were usually negative for IMP-3, maspin, S100P, CK17, MUC2, MUC4, and MUC5AC; (5) 60% of adenocar cinoma cases showed loss of expression of DPC4/SMAD4; and (6) strong background staining was frequently seen with fascin (including staining for endothelial cells and stromal cells), PSCA, and annexin A8.
Benign ducts were frequently positive for CA19-9, mesothelin, MUC1, MUC6, MOC31, PSCA, claudin 4, and claudin 18, which limits the application of these markers in distinguishing DAC from nonneoplastic pancreatic ducts.
Normal pancreatic ducts and acini are usually positive for MOC31, PSCA, claudin 4, and claudin 18, which limits the application of these markers in the distinction between pancreatic DAC and reactive ducts.